Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (688076.SS)
CNY29.11
+0.65 (+2.28%)
CN SHH Healthcare Medical - Pharmaceuticals
Address
No. 1378 Wenyi West Road 311121
Hangzhou, HA, CN
Hangzhou, HA, CN
CEO
Zi Quan Tong
Website
sinopep.com
IPO
2021-05-20
ISIN CNE1000051X5
Description
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was founded in 2009 and is headquartered in Hangzhou, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY29.11
+0.65 (+2.28%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.34
Float Shares
183.67M
Free Float %
58.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.51% | -2.90% | +0.37% | -8.07% | -21.20% | -20.85% | -13.08% | +24.54% | -54.69% | -61.50% | -61.50% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
29.11
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.22
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%+19.6% ★ Q1'26: -2.2% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-19.1% Q1'26: -16.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+6.7% ★ Q1'26: -3.4% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+18.1% ★ Q1'26: +29.4% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+6.8% ★ Q1'26: +10.7% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+2.2% Q1'26: +0.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×5.19× Q1'26: 4.53× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
651.29M
est: 651.00M (+0.0%)
|
1.03B
est: 1.46B (-29.4%)
|
1.62B
est: 1.67B (-2.9%)
|
1.94B
est: 2.01B (-3.2%)
|
2.35B
2.35B – 2.35B
+17.1% YoY
|
2.67B
2.67B – 2.67B
+13.5% YoY
|
| EBITDA |
231.35M
est: 214.48M (+7.9%)
|
320.99M
est: 497.37M (-35.5%)
|
675.49M
est: 568.36M (+18.8%)
|
553.78M
est: 681.39M (-18.7%)
|
797.89M
797.89M – 797.89M
+17.1% YoY
|
905.91M
905.91M – 905.91M
+13.5% YoY
|
| EBIT |
132.60M
est: 129.22M (+2.6%)
|
189.21M
est: 311.69M (-39.3%)
|
473.60M
est: 356.17M (+33.0%)
|
351.90M
est: 427.00M (-17.6%)
|
500.01M
500.01M – 500.01M
+17.1% YoY
|
567.70M
567.70M – 567.70M
+13.5% YoY
|
| Net Income |
129.11M
est: 94.19M (+37.1%)
|
162.94M
est: 504.80M (-67.7%)
|
404.39M
est: 424.47M (-4.7%)
|
332.42M
est: 543.95M (-38.9%)
|
694.87M
694.87M – 694.87M
+27.7% YoY
|
878.81M
878.81M – 878.81M
+26.5% YoY
|
| SGA |
186.98M
est: 156.34M (+19.6%)
|
268.23M
est: 314.46M (-14.7%)
|
339.13M
est: 359.34M (-5.6%)
|
164.58M
est: 430.79M (-61.8%)
|
504.45M
504.45M – 504.45M
+17.1% YoY
|
572.75M
572.75M – 572.75M
+13.5% YoY
|
| EPS |
0.44
est: 0.43 (+2.7%)
|
0.54
est: 1.61 (-66.4%)
|
1.34
est: 1.35 (-0.7%)
|
1.06
est: 1.73 (-38.7%)
|
2.21
2.21 – 2.21
+27.7% YoY
|
2.80
2.80 – 2.80
+26.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-93.95M
OE per share TTM
-0.30
Owner's Yield
-1.00%
Maintenance CapEx ratio
142.65%
Maint CapEx / Avg PPE
138.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 39.5K | 0.39% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 32.0K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
181.4K
Shares Outstanding
316.05M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guoqiang Shi | Senior Vice President & Director | — | male |
| Jianjun Jiang | Vice President | — | — |
| Wei Ding | Financial Director | — | male |
| Xiaohua Li | Senior Vice President | — | male |
| Yanwen Chen | Accounting Supervisor | — | — |
| Zhou Hua | Secretary of Board | — | female |
| Ziquan Tong | GM & Chairman | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688076.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
